Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eli Lilly and Company
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia
The primary objective of this study is to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving up to 52 weeks of LY2140023, given orally twice daily, ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Long-Term, Phase 2, Multicenter, Randomized, Open-Label, Comparative Safety Study of LY2140023 Versus Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia
The primary objective of this study is to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023, given orally twice daily for 24 weeks, versu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Study in Type 2 Diabetes
The primary objective of this study is to demonstrate that LY2605541 is noninferior to insulin glargine for the change in HbA1c from baseline to 52 weeks of treatment in insulin naive patients with T2...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Phase 2 Study to Evaluate LY2603618 in Combination with Pemetrexed in Patients with Advanced or Metastatic Non-small Cell Lung Cancer
The primary objective of this study is to estimate the overall response rate (ORR) for patients receiving pemetrexed in combination with LY2603618 for advanced or metastatic non-small cell lung canc...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Eli Lilly and Company
Update Il y a 4 ans
Etude H9H-MC-JBEG : étude de phase 1b (escalade de dose et cohorte d’expansion) visant à étudier la sécurité, la tolérance et l’efficacité d’un nouvel inhibiteur du facteur de croissance transformant-β (galunisertib), administré en association avec un anticorps anti-PD-L1 (durvalumab) chez des patients ayant un cancer du pancréas métastatique récurrent ou réfractaire. [essai clos aux inclusions]
Le cancer du pancréas prend naissance dans les cellules du pancréas. La tumeur cancéreuse est un groupe de cellules cancéreuses qui peuvent envahir et détruire le tissu voisin. Elle peut aussi se prop...
Country
France
organs
Pancréas
Specialty
Thérapies Ciblées
,
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhib...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients with Newly Diagnosed Glioblastoma without Methylation of the Promoter Gene of MGMT Enzyme – a Multicenter, Open-label, Uncontrolled Phase II Study
The study’s primary objective is evaluation of PFS-6 after diagnosis in patients with newly diagnosed glioblastoma without methylation of the promoter gene of MGMT enzyme treated with enzastaurin befo...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)
To compare the effect of LY500307 once daily for 24 weeks versus placebo treatment in improving the IPSS in men with LUTS and prostatic enlargement secondary to BPH.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Ltd
Update Il y a 4 ans
A Multi-center, Inpatient, Phase 2, Double-blind, Placebo-controlled Dose Ranging Study of LY2140023 in Patients with DSM-IV Schizophrenia
The primary objective of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to patients with schizophrenia twice daily for 4 weeks will demonstrate significantly...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Study in Prevention of Re-emergence of Depression Symptoms
Time to re-emergence of depressive symptoms
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
10
11
12
13
14
15
16
17
18
19
Next